Solving Mitochondrial Dysfunction to Transform Clinical Success
Welcome to the 3rd Annual Mitochondria-Related Drug Development Summit
Harnessing Novel Technologies to Develop and Demonstrate Safe and Efficacious Therapeutics to Regulators
The 3rd Annual Mitochondria-Related Drug Development Summit returns for the first in-person meeting of 80+ industry experts to explore the unique opportunities of targeting mitochondrial dysfunction in rare and prevalent diseases.
This September unlock the breakthroughs in our understanding of mitochondrial biology, structure, and function, to accelerate drug development. Recent IND approvals and clinical successes prove the near-endless potential of mitochondria to treat cardiovascular, renal, and neurodegenerative diseases.
Join us as we bring together rare mitochondrial disease experts and prevalent disease drug developers for a new era of targeting mitochondrial dysfunction.
World-Class Speaker Faculty Includes:
Eli Lilly & Company
Director of Preclinical Research
Chief Scientific Officer & Founder
Chief Executive Officer
Terry van Vleet
Head, Investigative Toxicology & Pathology
Vice President & Primary Focus Lead of Mitochondria
Previously Attending Companies Include:
From This Year’s Speakers:
“This summit brings together experts and thought leaders from all over the world to share their knowledge and insights into the development of drugs targeting mitochondrial diseases. I’m excited for the opportunity for to deepen my understanding of the topic, network with other attendees, and gain valuable insights into the latest research.” – Nicholas Hertz, Chief Scientific Officer & Founder, Mitokinin
“A small industry focused scientific meeting covering relevant topics in the challenging areas of rare mitochondrial disease and mitochondrial dysfunction in more prevalent disease is welcomed.” – John Campbell, Executive Director of Clinical Development, Stealth BioTherapeutics
Hear from last year’s attendees:
“Presentations had very high quality, discussions were very active. I liked very much the panel discussions; great questions, good messages from KOLs.” – Gyongyi Molnar, Scientific Fellow, Mitotherapeutix